Bulletin
Investor Alert

New York Markets Close in:

The Wall Street Journal Archives | Email alerts

April 16, 2021, 8:45 a.m. EDT

J&J privately asked rival COVID-19 vaccine makers to probe clotting risks

AstraZeneca was interested in joining forces to investigate the safety issue and communicate vaccine benefits and risks, but Pfizer and Moderna didn’t see the need for group action

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    AstraZeneca PLC ADR (AZN)
  • X
    AstraZeneca PLC (AZN)

or Cancel Already have a watchlist? Log In

By Jenny Strasburg, Jared S. Hopkins and Peter Loftus


Getty Images

Johnson & Johnson privately reached out to Covid-19 vaccine rivals to ask them to join an effort to study the risks of blood clots and speak with one voice about safety, but Pfizer Inc. and Moderna Inc. declined.

As concerns mounted last week over rare cases of blood clots, J&J /zigman2/quotes/201724570/composite JNJ -0.21%  asked AstraZeneca PLC /zigman2/quotes/200304487/composite AZN +1.20%   /zigman2/quotes/203048482/delayed UK:AZN +1.82%  as well as Pfizer /zigman2/quotes/202877789/composite PFE +0.79%  and /zigman2/quotes/205619834/composite MRNA -1.76%  to join its efforts looking into the reports, people familiar with the matter said. J&J, through emails and phone calls, also sought to build an informal alliance to communicate the benefits and risks of the shots and address any concerns raised among the public by the blood-clot cases, some of the people said.

Six women who got J&J’s vaccine developed clots, and one died, out of more than seven million doses administered across the U.S., according to federal health officials. The specific adverse event hasn’t been reported by people who received the Pfizer and Moderna shots, the officials said.

Pfizer and Moderna executives declined the offer, saying their vaccines appeared safe, the people said. The pair also objected because they didn’t see the need to duplicate the efforts of regulators and companies already looking for blood-clot cases and investigating the cause, the people said. One company’s concern: The safety of the Pfizer and Moderna shots could be tarnished by association, some of the people said. Only AstraZeneca, which had been buffeted by similar blood-clotting concerns for weeks, agreed, the people said.

An expanded version of this report appears at WSJ.com .

Most popular at WSJ.com :

Small group of COVID-19 infections seen in fully vaccinated patients .

Chauvin decides not to testify about Floyd’s death .

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 168.53
-0.35 -0.21%
Volume: 445,026
May 12, 2021 10:09a
P/E Ratio
29.75
Dividend Yield
2.52%
Market Cap
$444.73 billion
Rev. per Employee
$613,918
loading...
/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 54.75
+0.65 +1.20%
Volume: 1.70M
May 12, 2021 10:09a
P/E Ratio
35.99
Dividend Yield
2.50%
Market Cap
$141.71 billion
Rev. per Employee
$365,423
loading...
/zigman2/quotes/203048482/delayed
UK : U.K.: London
7,771.00 p
+139.00 +1.82%
Volume: 836,012
May 12, 2021 2:54p
P/E Ratio
33.97
Dividend Yield
2.66%
Market Cap
£100.19 billion
Rev. per Employee
£282,763
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 39.66
+0.31 +0.79%
Volume: 3.27M
May 12, 2021 10:09a
P/E Ratio
20.25
Dividend Yield
3.92%
Market Cap
$219.50 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 156.20
-2.80 -1.76%
Volume: 925,230
May 12, 2021 10:09a
P/E Ratio
125.26
Dividend Yield
N/A
Market Cap
$63.84 billion
Rev. per Employee
$617,996
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.